ClinicalTrials.gg
CompletedNCT04926116Updated Apr 7, 2022

A Study of AK3280 in Chinese Healthy Volunteers

A Phase 1 interventional study of AK3280 and Placebo in Healthy, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-07.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a randomized, double-blind, placebo-controlled, single-center, phase I study to evaluate the safety, tolerability, and pharmacokinetics of AK3280 in healthy Chinese subjects.

Read the detailed description

This phase I study is a randomized, double-blind, placebo-controlled, single-center clinical study in healthy subjects. The objectives of the study are to evaluate the safety, tolerability, and pharmacokinetics of AK3280. Approximately, 36 healthy Chinese subjects will be recruited and randomized to orally receive AK3280 or matching placebo. The total duration of the study will be approximately 25 days for each subject.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are willing to sign and date forms.
  • Male or female participants between 18 and 45 years of age, inclusive.
  • Have a bodyweight ≥50.0 kg (Male) or ≥45.0 kg (Female), and a (BMI) between 19.0 and 28.0 kg/m\^2, inclusive.
  • Participants are in good health without any significant clinical abnormalities on the basis of medical history related to heart, liver, kidneys, gastrointestinal tracts, or mental, central nervous, and metabolic disorders; physical examination (including vital signs); baseline laboratory test and 12-lead (ECG) results.
  • Participants (including male participants) who have no pregnancy plan and are willing to use an effective method of during the screening period and for three months thereafter without sperm or egg donation plans.
  • Participants who are capable to communicate with investigators and comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  • Allergic to any of the study drug ingredients or ineligible determined by the investigator due to a history of food or drug allergies.
  • Having an abnormal medical history in terms of digestive, urological, neurological, hematological, endocrine, oncological, pulmonary, immunological, cardiovascular, or psychiatric diseases or having histories of use any prescription, over-the-counter, herbs, vitamins, or vaccines within four weeks prior to study drug administration.
  • Intolerant to venipuncture or having difficulty in venous blood collection.
  • Having a personal history of drug and alcohol abuse, use of nicotine-containing products, receiving caffeine-containing drinks, taking grapefruit or food made of it, and medications, food, or beverages such as xanthines that could affect the ADME of study medication.
  • Having clinically significant abnormalities in vital sign measures and lab test results.
  • Female subjects are lactating at screening.
  • Previous participation in any clinical trial within 3 months prior to screening.
  • Inability to meet the study requirements in the opinion of the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    AK3280 Cohort 1

    Eligible subjects will be administered a single oral dose of 200 mg AK3280 under fasted conditions on Day 1. A multiple dosing period follows with daily 200 mg AK3280 b.i.d. administered with a concurrent low-fat meal intake from Day 4 to Day 16 and a 200 mg AK3280 q.d. dosing on Day 17.

    Drug: AK3280

  • Experimental
    AK3280 Cohort 2

    The dose level of AK3280 for Cohort 2 will be determined by the SRC (Safety Review Committee) based on the safety and PK data gleaned in Cohort 1. Subjects will receive AK3280 following the same dosing schedule as that in Cohort 1, i. e., a single oral dose of AK3280 under fasted conditions on Day 1, multiple AK3280 b.i.d. administration with a concurrent low-fat meal intake from Day 4 to Day 16, and an AK3280 q.d. dose on Day 17.

    Drug: AK3280

  • Experimental
    AK3280 Optional Cohort

    This is an optional dose cohort that the SRC will determine depending on the results of Cohorts 1 and 2, including the proposed dose level. Potential subjects in this cohort will also follow the same dosing scheme as those for Cohorts 1 and 2.

    Drug: AK3280

  • Placebo comparator
    Control Arm

    There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.

    Drug: Placebo

Interventions

  • DrugAK3280

    Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral

  • DrugPlacebo

    Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects with Adverse Events (AEs)

    An adverse event can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study medication, whether or not considered related to the study medication in this clinical trial.

    Time frame: From baseline up to approximately 6 weeks

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of AK3280

    The maximum observed plasma concentration of AK3280.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  2. Maximum Observed Plasma Concentration (Cmax) of AK3280 Metabolite

    The maximum observed plasma concentration of AK3280 metabolite.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  3. Observed trough plasma concentration at end of dosing interval (Ctrough) of AK3280

    The concentration of AK3280 reached immediately before the next dose administered.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  4. Observed trough plasma concentration at end of dosing interval (Ctrough) of AK3280 Metabolite

    The concentration of AK3280 metabolite reached immediately before the next dose administered.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  5. Measure maximum plasma concentration at steady state (Css max) of AK3280

    The maximum concentration of AK3280 reached at steady state.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  6. Measure maximum plasma concentration at steady state (Css max) of AK3280 Metabolite

    The maximum concentration of AK3280 metabolite reached at steady state.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  7. Time to Maximum Plasma Concentration (Tmax) of AK3280

    The time of occurrence of Cmax of AK3280

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  8. Time to Maximum Plasma Concentration (Tmax) of AK3280 Metabolite

    The time of occurrence of Cmax of AK3280 metabolite

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  9. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of AK3280

    The area under the plasma concentration-time curve from time zero up extrapolated to infinity of AK3280.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  10. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of AK3280 Metabolite

    The area under the plasma concentration-time curve from time zero up extrapolated to infinity of AK3280 metabolite.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  11. Area under the plasma concentration-time curve from time zero up to 12hrs (AUC 0-12h) of AK3280

    The area under the plasma concentration-time curve from time zero up to the 12hrs analytically quantifiable concentration of AK3280.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8, and 12hours post-dose)

  12. Area under the plasma concentration-time curve from time zero up to 12hrs (AUC 0-12h) of AK3280 Metabolite

    The area under the plasma concentration-time curve from time zero up to the 12hrs analytically quantifiable concentration of AK3280 metabolite.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8, and 12hours post-dose)

  13. Terminal Half-Life (t1/2) of AK3280

    The apparent elimination half-life of AK3280.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  14. Terminal Half-Life (t1/2) of AK3280 Metabolite

    The apparent elimination half-life of AK3280 metabolite.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  15. Apparent Oral Clearance (CL/F) of AK3280

    The oral clearance of AK3280.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  16. Apparent Oral Clearance (CL/F) of AK3280 Metabolite

    The oral clearance of AK3280 metabolite.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  17. Apparent volume of distribution during terminal phase (Vz/F) of AK3280

    The Vz/F of AK3280 will be calculated as CL/λz.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

  18. Apparent volume of distribution during terminal phase (Vz/F) of AK3280 Metabolite

    The Vz/F of AK3280 metabolite will be calculated as CL/λz.

    Time frame: Day1/Day17(pre-dose and 0.5,1,1.5,2,2.5,3,4,6,8,12hours post-dose), Day2/Day18(24hours post-dose), Day3/Day19(48hours post-dose), Day4/Day20(72hours post-dose); and Days6,8,10,14,15,16 (pre-dose)

07

Study locations

1 site
  • China-Japan Friendship Hospital
    Beijing, 100029, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Sep 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2021
First posted
Jun 14, 2021
StartActual
Jun 9, 2021
Primary completionActual
Sep 28, 2021
CompletionActual
Sep 28, 2021
Last update
Apr 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04926116
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 14, 2021
Start date
Jun 9, 2021
Primary completion
Sep 28, 2021
Completion
Sep 28, 2021
Last update
Apr 7, 2022

Study contacts

Jimmy Gu
study director · info@arkbiosciences.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK3280

Start the discussion